Skip to main content

Payers' Guide

Payers' Guide, FDA Approvals

Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer

Payers' Guide, FDA Approvals

Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Imbruvica (Ibrutinib), First-in-Class Bruton’s Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Invokamet (Canagliflozin plus Metformin HCl): First Fixed-Dose Combination with an SGLT2 Inhibitor Approved for the Treatment of Patients with Type 2 Diabetes

Payers' Guide, FDA Approvals

Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes

Payers' Guide, FDA Approvals

Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Ofev (Nintedanib): First Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Idiopathic Pulmonary Fibrosis

Payers' Guide, FDA Approvals

Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis

Payers' Guide, FDA Approvals

Sivextro (Tedizolid Phosphate) Approved for the Treatment of Adults with Acute Bacterial Skin and Skin- Structure Infections

Page 12 of 19
Results 111 - 120 of 185